What are the recommended laboratory tests for diagnosing insulinoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Laboratory Tests for Diagnosing Insulinoma

The diagnosis of insulinoma requires a supervised 48-72 hour fast with measurement of glucose, insulin, C-peptide, and proinsulin at the time of hypoglycemia, using specific diagnostic thresholds to confirm inappropriate insulin secretion. 1

Gold Standard Diagnostic Test

The supervised prolonged fast is the first-line diagnostic test for insulinoma and should be performed until hypoglycemia occurs or the 48-72 hour time limit is reached. 1 This test requires hospitalization due to the risk of severe hypoglycemic episodes but remains the most reliable diagnostic approach. 2

Laboratory Criteria at Time of Hypoglycemia

When hypoglycemia develops during the supervised fast (blood glucose <40-45 mg/dL), the following laboratory values confirm the diagnosis of insulinoma: 1

  • Insulin level >3 mcIU/mL (inappropriately elevated for the degree of hypoglycemia) 1
  • C-peptide ≥0.6 ng/mL (confirms endogenous insulin production) 1
  • Proinsulin levels ≥5 pmol/L (elevated proinsulin-to-insulin ratio strongly suggests islet cell tumor) 3, 1
  • Insulin-to-glucose ratio ≥0.3 (demonstrates inappropriate insulin secretion relative to glucose) 1

Critical Role of Each Laboratory Test

Insulin measurement demonstrates inappropriately increased plasma insulin concentrations in the face of low glucose, which is the hallmark of insulinoma. 3 The persistence of insulin secretion despite hypoglycemia distinguishes insulinoma from other causes of hypoglycemia. 3

C-peptide measurement is essential because it differentiates endogenous hyperinsulinemia (insulinoma) from surreptitious exogenous insulin administration. 3, 1 Elevated C-peptide levels (≥0.6 ng/mL) confirm that the insulin is being produced by the patient's own pancreatic tissue rather than being injected. 3

Proinsulin measurement provides additional diagnostic specificity, as an increased ratio of fasting proinsulin to insulin strongly suggests the presence of an islet cell tumor. 3 Some rare insulinomas secrete predominantly proinsulin rather than processed insulin, and these tumors would go undetected if only insulin levels were measured using modern specific immunometric assays. 4 Proinsulin assay is particularly helpful when immunoreactive insulin measured by specific new methods appears normal. 4

Important Caveats and Pitfalls

Avoid measuring sulfonylurea levels to exclude factitious hypoglycemia from oral hypoglycemic agents, as the absence of plasma sulfonylurea combined with elevated insulin and C-peptide confirms endogenous hyperinsulinism. 5

Be aware that modern insulin assays have excellent specificity with no cross-reactivity with intact or Des 31,32 proinsulin, but this means rare proinsulin-secreting tumors require specific proinsulin measurement for diagnosis. 4

The absence of inappropriately elevated glucose, insulin, and proinsulin concentrations during fasting hypoglycemia makes the diagnosis of an islet cell tumor most unlikely, and alternative explanations should be sought. 3

Proton pump inhibitors can cause spuriously elevated chromogranin A levels, which may complicate the diagnostic workup if neuroendocrine tumor markers are being assessed. 1

Alternative Testing Considerations

While a 5-hour oral glucose tolerance test with insulin-to-glucose and C-peptide-to-glucose ratios has been studied as an outpatient alternative, this approach is not recommended as first-line testing. 6 The supervised prolonged fast remains the gold standard because insulinomas typically cause fasting rather than postprandial hypoglycemia, and some insulinomas may be glucose-responsive, making provocative testing unreliable. 7

References

Guideline

Diagnostic and Treatment Approach for Insulinoma

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Insulin secretion and insulin-producing tumors.

Expert review of endocrinology & metabolism, 2010

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Proinsulin-secreting neuroendocrine tumor of the pancreas.

Journal of endocrinological investigation, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.